Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs

Journal of Controlled Release

Volumn 111, Issue 1-2, 2006, Pages 56-64

  Jinno, Jun Ichi ^a,b   Kamada, Naoki ^a   Miyake, Masateru ^a   Yamada, Keigo ^a   Mukai, Tadashi ^a   Odomi, Masaaki ^a   Toguchi, Hajime ^a   Liversidge, Gary G ^c   Higaki, Kazutaka ^b   Kimura, Toshikiro ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c Elan Drug Delivery Inc   (United States)

Author keywords

Bioavailability; Cilostazol; Dissolution; Food effect; NanoCrystal; Particle size reduction

Indexed keywords

ABSORPTION; NANOSTRUCTURED MATERIALS; PARTICLE SIZE ANALYSIS; REDUCTION; SOLUBILITY; WATER;

BIOAVAILABILITY; CILOSTAZOL; FOOD EFFECT; NANOCRYSTAL; PARTICLE SIZE REDUCTION;

DRUG PRODUCTS;

'NANOCRYSTAL'; CILOSTAZOL; DOCUSATE SODIUM; HYDROXYPROPYLCELLULOSE;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; FOOD DRUG INTERACTION; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; TECHNOLOGY;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOGS; FASTING; INTESTINAL ABSORPTION; NANOSTRUCTURES; PARTICLE SIZE; PLATELET AGGREGATION INHIBITORS; POWDERS; SOLUBILITY; SUSPENSIONS; TETRAZOLES; TIME FACTORS; WATER;

EID: 33344478634     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.11.013     Document Type: Article

References (33)

1. Y. Kimura, T. Tani, T. Kanbe, and K. Watanabe Effect of cilostazol on platelet aggregation and experimental thrombosis Arzneimittelforschung 35 1985 1144 1149
2. H.G. Beebe Intermittent claudication: effective medical management of a common circulatory problem Am. J. Cardiol. 87 2001 14D 18D
3. D.L. Dawson Comparative effects of cilostazol and other therapies for intermittent claudication Am. J. Cardiol. 87 2001 19D 27D
4. J. Kambayashi, Y. Liu, B. Sun, Y. Shakur, M. Yoshitake, and F. Czerwiec Cilostazol as a unique antithrombotic agent Curr. Pharm. Des. 9 2003 2289 2302
5. S.R. Money, J.A. Herd, J.L. Isaacsohn, M. Davidson, B. Cutler, J. Heckman, and W.P. Forbes Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease J. Vasc. Surg. 27 1998 267 275
6. F. Gotoh, H. Tohgi, S. Hirai, A. Terashi, Y. Fukuuchi, E. Otomo, Y. Shinohara, E. Itoh, T. Matsuda, T. Sawada, T. Yamaguchi, K. Nishimaru, and Y. Ohashi Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction J. Stroke Celebrovasc. Dis. 9 2000 147 157
7. T. Shimizu, T. Osumi, K. Niimi, and K. Nakagawa Physico-chemical properties and stability of cilostazol Arzneimittelforschung 35 1985 1117 1123
8. H. Toyobuku, I. Tamai, K. Ueno, and A. Tsuji Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug J. Pharm. Sci. 92 2003 2249 2259
9. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
10. H. Akiyama, S. Kudo, and T. Shimizu The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man Arzneimittelforschung 35 1985 1133 1140
11. H. Akiyama, S. Kudo, and T. Shimizu The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man Arzneimittelforschung 35 1985 1124 1132
12. S.L. Bramer, and W.P. Forbes Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics Clin. Pharmacokinet. 37 Suppl 2 1999 13 23
13. B.N. Singh Effects of food on clinical pharmacokinetics Clin. Pharmacokinet. 37 1999 213 255
14. A.A. Noyes, and W.R. Whitney The rate of solution of solid substances in their own solutions J. Am. Chem. Soc. 19 1897 930 934
15. N. Rasenack, and B.W. Muller Micron-size drug particles: common and novel micronization techniques Pharm. Dev. Technol. 9 2004 1 13
16. R.E. O'Connor, and E.G. Rippie Powders A.R. Gennaro J.B. Schwartz Remington's Pharmaceutical Sciences 18th edition 1990 Mack Publishing Company Easton, PA 1615 1632
17. G.G. Liversidge, and K.C. Cundy Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs Int. J. Pharm. 125 1995 91 97
18. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly-water-soluble compounds Eur. J. Pharm. Sci. 18 2003 113 120
19. Y. Wu, A. Loper, E. Landis, L. Hettrick, L. Novak, K. Lynn, C. Chen, K. Thompson, R. Higgins, U. Batra, S. Shelukar, G. Kwei, and D. Storey The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human Int. J. Pharm. 285 2004 135 146
20. J.B. Dressman, G.L. Amidon, C. Reppas, and V.P. Shah Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms Pharm. Res. 15 1998 11 22
21. H.M. Abdou Dissolution A.R. Gennaro J.B. Schwartz Remington's Pharmaceutical Sciences 18th edition 1990 Mack Publishing Company Easton, PA 589 602
22. W.I. Higuchi, N.F.H. Ho, and A.H. Goldberg Theories of dispersion techniques L. Lachman H.A. Lieberman J.L. Kaning The Theory and Particle of Industrial Pharmacy 1970 Lea and Febiger Philadelphia 120 136
23. R.J. Hints, and K.C. Johnson The effect of particle size distribution on dissolution rate and oral absorption Int. J. Pharm. 51 1989 9 17
24. J.B. Dressman, and D. Fleisher Mixing-tank model for predicting dissolution rate control or oral absorption J. Pharm. Sci. 75 1986 109 116
25. K.C. Johnson Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption Drug Dev. Ind. Pharm. 29 2003 833 842
26. A.T. Lu, M.E. Frisella, and K.C. Johnson Dissolution modeling: factors affecting the dissolution rates of polydisperse powders Pharm. Res. 10 1993 1308 1314
27. W. Hyduk, and H. Laudie Prediction of diffusion coefficients for nonelectrolytes in diluted aqueous solutions AIChE J. 20 1974 611 615
28. B.E. Poling, J.M. Prausnitz, and J.P. O'Connell Pressure-volume- temperature relationship of pure gases and liquids B.E. Poling J.M. Prausnitz J.P. O'Connell The Properties of Gases and Liquids 2000 McGraw Hill Book Co New York 33 34
29. N. Kondo, T. Iwao, H. Masuda, K. Yamanouchi, Y. Ishihara, N. Yamada, T. Haga, Y. Ogawa, and K. Yokoyama Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region Chem. Pharm. Bull. (Tokyo) 41 1993 737 740
30. J.B. Dressman, and C. Reppas In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci. 11 Suppl. 2 2000 S73 S80
31. E. Nicolaides, E. Galia, C. Efthymiopoulos, J.B. Dressman, and C. Reppas Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data Pharm. Res. 16 1999 1876 1882
32. E. Nicolaides, M. Symillides, J.B. Dressman, and C. Reppas Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 2001 380 388
33. T. Kimura, and K. Higaki Gastrointestinal transit and drug absorption Biol. Pharm. Bull. 25 2002 149 164